PET imaging of blood flow and glucose metabolism in localized musculoskeletal tumors of the extremities

Nuclear Medicine and Biology

Volumn 38, Issue 2, 2011, Pages 295-300

  Lindholm, Paula ^a,b   Sutinen, Eija ^a,b   Oikonen, Vesa ^b   Mattila, Kimmo ^a   Tarkkanen, Maija ^c   Kallajoki, Markku ^a   Aro, Hannu ^a   Böhling, Tom ^c   Kivioja, Aarne ^c   Elomaa, Inkeri ^c   Minn, Heikki ^a,b  

^a TURKU UNIVERSITY HOSPITAL   (Finland)

^b TURKU PET CENTRE   (Finland)

^c HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

Blood flow; Metabolism; Musculoskeletal tumors; PET

Indexed keywords

ANTINEOPLASTIC AGENT; FLUORODEOXYGLUCOSE F 18; OXYGEN 15; WATER;

ADOLESCENT; ADULT; AGED; ANEURYSMAL BONE CYST; ARTERY BLOOD FLOW; ARTICLE; AUTORADIOGRAPHY; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ARTICLE; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DIAGNOSTIC IMAGING; DISEASE ACTIVITY; DISTANT METASTASIS; DRUG TUMOR LEVEL; FEMALE; GLUCOSE METABOLISM; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; ISOTOPE LABELING; MALE; METABOLIC RATE; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOSARCOMA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; RECURRENT CANCER; SOFT TISSUE SARCOMA; TUMOR BLOOD FLOW;

ADOLESCENT; ADULT; AGED; BLOOD CIRCULATION; BONE NEOPLASMS; EXTREMITIES; FEMALE; FLUORODEOXYGLUCOSE F18; GLUCOSE; HUMANS; MALE; MIDDLE AGED; OXYGEN RADIOISOTOPES; POSITRON-EMISSION TOMOGRAPHY; SARCOMA; TREATMENT OUTCOME; WATER;

EID: 79551682167     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2010.08.012     Document Type: Article

References (32)

1. Verstraete K., Lang P. Bone and soft tissue tumors: the role of contrast agents for MR imaging. Eur J Radiol 2000, 34(3):229-246.
2. Bastiaannet E., Groen H., Jager P., Cobben D., van der Graaf W., Vaalburg W., et al. The value of FDG-PET in the detection, grading and response to therapy of soft tissue and bone sarcomas; a systematic review and meta-analysis. Cancer Treat Rev 2004, 30:83-101.
3. Tateishi U., Yamaguchi U., Seki K., Terauchi T., Arai Y., Kim E. Bone and soft-tissue sarcoma: preoperative staging with fluorine 18 fluorodeoxyglucose PET/CT and conventional imaging. Radiology 2007, 245:839-847.
4. Gerth H., Juergens K., Dirksen U., Gerss J., Schober O., Franzius C. Significant benefit of multimodal imaging: PET/CT compared with PET alone in staging and follow-up of patients with Ewing tumors. J Nucl Med 2007, 48:1932-1939.
5. 18fluoro-deoxyglucose in the detection of local recurrence and distant metastases of pediatric sarcoma. Pediatr Blood Cancer 2007, 49:901-905.
6. 18F]Fluorodeoxyglucose positron emission tomography predicts outcome for Ewing sarcoma family of tumors. J Clin Oncol 2005, 23:8828-8834.
7. Schuetze S., Rubin B., Vernon C., Hawkins D., Bruckner J., Conrad E., et al. Use of positron emission tomography in localized extremity soft-tissue sarcoma treated with neoadjuvant chemotherapy. Cancer 2005, 103:339-348.
8. 18F-FDG PET/CT in patients with sarcomas: interobserver variability of quantitative parameters in treatment-induced changes in histopathologically responding and non-responding tumors. J Nucl Med 2008, 49:1038-1046.
9. Stroobants S., Goeminne J., Seegers M., Dimitrijevic S., Dupont P., Nuyts J, et al. 18-FDG-positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec). Eur J Cancer 2003, 39:2012-2020.
10. Meyer J., Nadel H., Marina N., Womer R., Brown K., Eary J., et al. Imaging guidelines for children with Ewing sarcoma and osteosarcoma: a report from the Children's Oncology Group Bone Tumor Committee. Pediatr Blood Cancer 2008, 51:163-170.
11. Fukumura D., Jain R. Tumor microvasculature and microenvironment: targets for anti-angiogenesis and normalization. Microvasc Res 2007, 74:72-84.
12. Miller J., Pien H., Sahani D., Sorensen A., Thrall J. Imaging angiogenesis: applications and potential for drug development. J Natl Cancer Inst 2005, 97:172-187.
13. Ogawa T., Uemura K., Shishido F., Yamaguchi T., Murakami M., Inugami A., et al. Changes in cerebral blood flow, and oxygen and glucose metabolism following radiochemotherapy of gliomas: a PET study. J Comput Assist Tomogr 1988, 12(2):290-297.
14. Mineura K., Sasajima T., Kowada M., Ogawa T., Hatazawa J., Shishido F., et al. Perfusion and metabolism in predicting the survival of patients with cerebral gliomas. Cancer 1994, 73:2386-2394.
15. Beaney R., Lammertsma A., Jones T., McKenzie C., Halnan K. Positron emission tomography for in-vivo measurement for regional blood flow, oxygen utilization, and blood volume in patients with breast carcinoma. Lancet 1984, 131-134.
16. Mankoff D., Dunnwald L., Gralow J., Ellis G., Charlop A., Lawton T., et al. Blood flow and metabolism in locally advanced breast cancer: relationship to response to therapy. J Nucl Med 2002, 43:500-509.
17. Zasadny K., Tatsumi M., Wahl R. FDG metabolism and uptake versus blood flow in women with untreated primary breast cancers. Eur J Nucl Med 2003, 30:274-280.
18. 18F-FDG PET study. Nucl Med Commun 2007, 28:789-797.
19. Dunnwald L., Gralow J., Ellis G., Livingston R., Linden H., Specht J., et al. Tumor metabolism and blood flow changes by positron emission tomography: relation to survival in patients treated with neoadjuvant chemotherapy for locally advanced breast cancer. J Clin Oncol 2008, 26:4449-4457.
20. 18F]fluoroethylnitroimidazole PET. J Nucl Med 2001, 42:1643-1652.
21. Lehtiö K., Eskola O., Viljanen T., Oikonen V., Grönroos T., Sillanmäki L., et al. Imaging perfusion and hypoxia with PET to predict radiotherapy response in head and neck cancer. Int J Radiat Oncol Biol Phys 2004, 59:971-982.
22. Smeland S., MUdouble acuteller C., Alvegaard T.A., Wiklund T., Wiebe T., Björk O., et al. Scandinavian Sarcoma Group Osteosarcoma Study SSG VIII: prognostic factors for outcome and the role of replacement salvage chemotherapy for poor histological responders. Eur J Cancer 2003, 39:488-494.
23. Ferrari S., Smeland S., Mercuri M., Bertoni F., Longhi A., Ruggieri P., et al. Neoadjuvant chemotherapy with high-dose ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: a joint study by the Italian and Scandinavian Sarcoma Groups. J Clin Oncol 2005, 23:8845-8852.
24. Sipilä H., Clark J., Peltola O., Teräs M. An automatic [15O]H2O production system for heart and brain studies. J Labelled Compounds Radiopharmaceuticals 2001, 44(Suppl 1):S1066-1068.
25. Ruotsalainen U., Raitakari M., Nuutila P., Oikonen V., Sipilä H., Teräs M., et al. Quantitative blood flow measurement of skeletal muscle using oxygen-15-water and PET. J Nucl Med 1997, 38:314-319.
26. George S., Merriam P., Maki R., van den Abbeele A., Yap J., Akhurst T., et al. Multicenter phase II trial of sunitinib in the treatment of nongastrointestinal stromal tumor sarcomas. J Clin Oncol 2009, 27:3154-3160.
27. Nieweg O., Pruim J., Hoekstra H., Paans A., Vaalburg W., Oldhoff J., et al. Positron emission tomography with fluorine-18-fluorodeoxyglucose for the evaluation of therapeutic isolated regional limb perfusion in an patient with soft-tissue sarcoma. J Nucl Med 1994, 35:90-92.
28. 11C]-Tyrosine PET to evaluate response to hyperthermic isolated limb perfusion for locally advanced soft-tissue sarcoma and skin cancer. J Nucl Med 1999, 40:262-267.
29. 15O]water. J Nucl Med 2000, 41:1784-1792.
30. Miles K., Griffiths M., Keith C. Blood flow-metabolic relationships are dependent in tumour size in non-small cell lung cancer: a study using quantitative contrast-enhanced computed tomography and positron emission tomography. Eur J Nucl Med Mol Imaging 2006, 33:22-28.
31. Komar G., Kauhanen S., Liukko K., Seppänen M., Kajander S., Ovaska J., et al. Decreased blood flow with increased metabolic activity: a novel sign of pancreatic tumor aggressiveness. Clin Cancer Res 2009, 15(17):5511-5517.
32. 15O-PET and DCE-MRI to measure tumor blood flow. Oncologist 2008, 13:631-644.